FOUNDATIONONE®LIQUID CDx

Next-generation test, improved report

EU REPORT

Page 1: Quick, clear access to the information you need most[1]

FOUNDATIONONE®LIQUID CDx

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT 999999999, FR
TUMOR TYPE Lung adenocarcinoma
COUNTRY CODE FR
REPORT DATE 28 August 2020
ORDERED TEST # ORD-XXXXXXX-XX

PATIENT
DISEASE Lung adenocarcinoma
NAME 999999999, FR
DATE OF BIRTH Not Given
SEX Not Given
MEDICAL RECORD # Not Given

PHYSICIAN
ORDERING PHYSICIAN Not Given
MEDICAL FACILITY Not Given
ADDITIONAL RECIPIENT Not Given
MEDICAL FACILITY ID Not Given
PATHOLOGIST Not Given

SPECIMEN
SPECIMEN ID Not Given
SPECIMEN TYPE Blood
DATE OF COLLECTION Not Given
SPECIMEN RECEIVED Not Given

Genomic Signatures 1
Blood Tumor Mutational Burden - 5 Muts/Mb
Microsatellite status - Cannot Be Determined
Tumor Fraction - 13%

Gene Alterations 2
For a complete list of the genes assayed, please refer to the Appendix.
EGFR exon 19 deletion (L747_A750>P)
TP53 R267P

5 Therapies Approved in the EU
0 Therapies with Lack of Response
10 Clinical Trials 3

GENOMIC SIGNATURES
Blood Tumor Mutational Burden - 5 Muts/Mb
Microsatellite status - Cannot Be Determined
Tumor Fraction - 13%

GENE ALTERATIONS	VAF %
EGFR **-** exon 19 deletion (L747_A750>P)	0.20%

10 Trials see p. 11 5

4 THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. see Genomic Signatures section	
Unable to determine Microsatellite status due to insufficient evidence of genomic instability.	
Tumor fraction is an estimate of the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample based on observed aneuploid instability.	
THERAPIES APPROVED IN THE EU (IN PATIENT'S TUMOR TYPE)	**THERAPIES APPROVED IN THE EU (IN OTHER TUMOR TYPE)**
Afatinib 1	
Dacomitinib 1	
Erlotinib 1	
Gefitinib 1	
Osimertinib 1	

4 *NCCN Category*

Electronically Signed by Julia A. Elvin, M.D., Ph.D. • 01 June 2020
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M. M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. • 1-888-988-3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 • CLIA: 22D2027531

PAGE 1 of 17


6


7

1 **Genomic signatures.**
bTMB and MSI* status, that may help inform eligibility for immunotherapy

2 **Gene alterations.**
Clinically-relevant alterations in >300 tested cancer-related genes

3 **Pertinent negative results.**
Rules out important alterations that are not present

4 **Therapies with clinical benefit.**
Therapies approved in the EU** for your patient's genomic signatures and gene alterations

5 **Clinical trials.**
Relevant trials that your patient may be eligible for, based on their genomic profile and geographic location

6 **Gene alterations with no reportable options.**
To help you rule out uncertainty and determine the most appropriate course of action

7 **Variant allele frequency percentage (VAF%).**
for base substitutions and insertions

Reports vary according to regional differences, e.g. EU reports list EU-approved therapy options to support clinical decision-making.
*FoundationOne Liquid CDx reports MSI-H status.
**Therapies contained in this report may have been approved through a centralised EU procedure or a national procedure in an EU Member State. For additional information on the NCCN categories please refer to the NCCN Compendium® (www.nccn.org).
MSI, microsatellite instability. bTMB, blood tumour mutational burden.

FOUNDATION MEDICINE® | Roche

FOUNDATIONONE® LIQUID CDx

Page 2 onwards: detailed supporting information and guidance

Gives important background information **on genomic signatures and gene alterations** in your patient's tumour, notably the evidence behind associated potential treatment strategies.

Provides evidence-based insights on the therapies that **match your patient's profile, in their tumour type and others**.

Details **ongoing clinical trials** that your patient may be eligible for, with trial NCT number, phase, title and locations.



Lists **variants of unknown significance** (VUS), included in the event that they become clinically meaningful in the future.



Tells you **what we tested** to give you a comprehensive picture of our service.

FoundationOne Liquid CDx report: For insights for your patients at optimal times beneficial to their treatment journey

FOR MORE INFORMATION PLEASE CONTACT YOUR ROCHE REPRESENTATIVE

www.foundationmedicine.se | 08-726 11 00

1. Data on file: FoundationOne Liquid CDx mock report, 2020.

www.foundationmedicine.se | 08-726 11 00

M-SE-00000431 | Date of preparation: September 2020

FOUNDATION MEDICINE®

Roche